Trial Profile
A Phase II Study of Venetoclax (ABT-199) Consolidation for Patients Currently Receiving Ibrutinib or Acalabrutinib for High-risk CLL
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 12 May 2022 Planned number of patients changed from 60 to 90.
- 12 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2025.
- 12 May 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2025.